Vaxart Inc
VXRT
Get informed when a big investor buys or sells
+ FollowMarket Cap$118.6M
Close$
$-0.38
180.8% downside
Current Fair Value
180.8% downsideOvervalued by 180.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $118.60 Million |
|---|---|
| Enterprise Value | $75.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.07 |
| Beta | 1.06 |
| Outstanding Shares | 242,165,410 |
Return
| Return on Equity | 46.85% |
|---|---|
| Return on Assets | 23.36% |
| Return on Invested Capital | 48.24% |
Valuation & Multiples
| P/E Ratio | 3.27 |
|---|---|
| PEG | -32.81 |
| Price to Sales | 0.47 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.31 |
| Enterprise Value to EBIT | 1.7 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$26.21 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$26.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▲ 0.02% |
|---|---|
| Total Invested | $39,004▲ 140.13% |
| Investors Holding | 5▲ 1.00% |
ESG Score
No data
About Vaxart Inc
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped wit...